Recent blog posts
Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure
Hot Spotlight
3 min read
Sosei Heptares has been renamed Nxera Pharma, with updates made to its corporate structure
28 April 2024
On March 27th, Japan's Sosei Group Corporation announced that their board members and executives were reelected during the 34th Annual General Meeting and subsequent board meeting in Tokyo.
Read →
Breakthrough in Parkinson's Treatment: Positive Phase 3 Trial Results for Cerevel's Tavapadon
Hot Spotlight
2 min read
Breakthrough in Parkinson's Treatment: Positive Phase 3 Trial Results for Cerevel's Tavapadon
28 April 2024
On April 18th, Cerevel reported positive results from its Phase 3 TEMPO-3 trial for tavapadon, a D1/D5 receptor partial agonist aimed at treating Parkinson's disease.
Read →
Progress in the Research of Therapeutic Peptides Targeting GPCRs
Hot Spotlight
10 min read
Progress in the Research of Therapeutic Peptides Targeting GPCRs
25 April 2024
GPCRs, as key signal transduction molecules on the cell surface, regulate various physiological processes and constitute one-third of the targets for clinical drug applications.
Read →
Tavapadon: A New Hope in the Battle Against Parkinson's Disease
Hot Spotlight
7 min read
Tavapadon: A New Hope in the Battle Against Parkinson's Disease
24 April 2024
The challenge is finding how to effectively alleviate these symptoms while maintaining sufficient safety. Tavapadon has found a balance in addressing this issue.
Read →
Amolyt Pharma and Core Peptide Patent Product Acquired by AstraZeneca
Hot Spotlight
4 min read
Amolyt Pharma and Core Peptide Patent Product Acquired by AstraZeneca
19 April 2024
In March, British pharmaceutical giant AstraZeneca announced its intention to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing innovative therapies for rare endocrine diseases.
Read →
Design of Biased Agonists Targeting the Apelin Receptor
Hot Spotlight
6 min read
Design of Biased Agonists Targeting the Apelin Receptor
15 April 2024
The study reveals a structure-guided strategy for biased drug optimization and has led to the development of two biased agonist drug candidates targeting the APLNR receptor.
Read →
Nature: Design of a Novel Bivalent Analgesic Targeting the μ-Opioid Receptor
Hot Spotlight
6 min read
Nature: Design of a Novel Bivalent Analgesic Targeting the μ-Opioid Receptor
10 April 2024
Opioid receptors are crucial for pain relief, blocking pain signal transmission to reduce acute and chronic pain like post-surgery and cancer pain.
Read →
Genfleet Therapeutics Announces the Potential Molecular Structure of Its Oral KRAS G12D Inhibitor through the Publication of its Patent
Hot Spotlight
5 min read
Genfleet Therapeutics Announces the Potential Molecular Structure of Its Oral KRAS G12D Inhibitor through the Publication of its Patent
9 April 2024
On March 28th, Genfleet Therapeutics publicly announced a patent for an oral KRAS G12D inhibitor, with the patent number WO2024061370A1.
Read →
Bivalent Ligands for GPCRs
Hot Spotlight
3 min read
Bivalent Ligands for GPCRs
9 April 2024
Bitopic ligands of GPCRs (G protein-coupled receptors) refer to a single chemical entity composed of two pharmacophoric groups covalently linked together.
Read →
Cell: Designing dual-acting drugs targeting GPCRs using a cheminformatics approach based on variable scaffolds
Hot Spotlight
8 min read
Cell: Designing dual-acting drugs targeting GPCRs using a cheminformatics approach based on variable scaffolds
9 April 2024
On March 28th, the journal "Cell" published an online research paper titled "Flexible Scaffold-based Cheminformatics Approach for Polypharmacological Drug Design".
Read →
The small-molecule CXCR4 antagonist Mavorixafor is used for the treatment of WHIM syndrome and chronic neutropenia
Hot Spotlight
4 min read
The small-molecule CXCR4 antagonist Mavorixafor is used for the treatment of WHIM syndrome and chronic neutropenia
9 April 2024
X4 Pharmaceuticals announced preliminary results from its Phase 2 trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without injected G-CSF in patients with idiopathic, cyclic, or congenital neutropenia.
Read →
Pharvaris is developing a bradykinin B2 receptor antagonist for the treatment of hereditary angioedema
Hot Spotlight
4 min read
Pharvaris is developing a bradykinin B2 receptor antagonist for the treatment of hereditary angioedema
9 April 2024
Deucrictibant is a new, potent oral small-molecule bradykinin B2 receptor antagonist, originally developed by the Pharvaris team.
Read →